Amgen Phase 3 Aranesp RED-HF trial fails to meet primary endpoint

Amgen has reported that Phase 3 Aranesp (darbepoetin alfa) RED-HF (reduction of events with darbepoetin alfa in heart failure) trial did not meet the primary endpoint of reducing the composite endpoint of time to death from any cause or first hospita…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news